Aslan Fred 4
4 · Artiva Biotherapeutics, Inc. · Filed May 19, 2026
Research Summary
AI-generated summary of this filing
Artiva Biotherapeutics (ARTV) CEO Fred Aslan Sells Shares
What Happened
Fred Aslan, Chief Executive Officer of Artiva Biotherapeutics (ARTV), sold 27,116 shares on 2026-05-19 in an open-market/automatic sale for total proceeds of about $244,253. The weighted-average sale price was $9.0077 (price range $8.7383–$9.0104). The filing reports the sale as a disposition (transaction code S).
Key Details
- Transaction date: 2026-05-19 (filed same day). Filing appears timely.
- Shares sold: 27,116 at a weighted-average price of $9.0077; total proceeds ≈ $244,253.
- Price range reported: $8.7383 to $9.0104 (issuer can provide per-share price breakdown on request).
- Shares owned after transaction: Not disclosed in this Form 4.
- Footnote F1: Sale was an automatic "sell-to-cover" to satisfy tax withholding on vested restricted stock units (not at the CEO's discretion).
- Footnote F2: Confirms weighted-average price and price range; full per-price breakdown available on request.
Context
This was a routine sell-to-cover related to RSU tax withholding, which is a common administrative transaction and not necessarily a signal about the CEO’s view of the stock. For retail investors, purchases generally carry more informational weight than automatic sales to cover taxes.
Insider Transaction Report
Form 4
Aslan Fred
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-05-19$9.01/sh−27,116$244,253→ 1,535,082 total
Footnotes (2)
- [F1]The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- [F2]The weighted average sale price for the transaction reported was $9.0077, and the range of prices were between $8.7383 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Signature
/s/ Andrew Cronauer, Attorney-in-Fact|2026-05-19